Nevertheless, our study supports investigation of 40Hz GENUS in larger, longer clinical trials in AD to determine whether the findings reported here are robust and reproducible and to investigate effects of 40Hz GENUS on amyloid and tau biomarkers of AD. The gene discussed is MAPT; the disease is Alzheimer disease.